SecBot SecBot
144 ·Filed May 12, 2026

XFOR

X4 Pharmaceuticals, Inc
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC0001276750-26-000004
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider sale tied to RSU vesting. The dollar amount is immaterial relative to market cap. No immediate trading signal — monitor for any cluster of insider sales or larger disposals by senior management.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
XFOR ▲ +9.69% at T+60d
NEUTRAL call +9.69% · α vs SPY +5.25% · entry $4.23 → $4.64
Entry = T+0 close
May 12, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.00%
$4.23
settled 6mo ago
T+5d
-13.95%
call -13.95% · α -12.79%
$3.64
settled 5mo ago
T+20d
-8.27%
call -8.27% · α -7.66%
$3.88
settled 5mo ago
T+60d
+9.69%
call +9.69% · α +5.25%
$4.64
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

David Kirske, an officer of X4 Pharmaceuticals, filed a Form 144 notice of intent to sell 16,961 shares of common stock valued at approximately $72,820. The shares were acquired through restricted stock unit vesting on May 11, 2026. This is a routine insider sale following equity compensation vesting and represents a small fraction of the company's $424M market cap.

Key Facts

  • Filer: David Kirske, an officer of X4 Pharmaceuticals
  • Proposed sale: 16,961 shares of common stock
  • Approximate value: $72,820.41
  • Shares acquired via restricted stock unit vesting on May 11, 2026
  • Sale intended to be executed through Morgan Stanley Smith Barney LLC
  • Filing date: May 12, 2026

Financial Impact

Approximately $72,820 — less than 0.02% of XFOR's $424M market cap

dilution

Risk Factors

  • Insider selling could increase if additional officers follow suit
  • No material risk from this isolated filing

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001276750-26-000004
Document: 0001276750-26-000004-index.html0001276750-26-000004
Document: 0001276750-26-000004.txt0001276750-26-000004
15 reports for XFOR
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for XFOR — sortable, filterable
TypeNow
Oct 8, 2026
18d ago
8-K
MIXED ★ 6/10
$2.91awaiting T+20—$3.10 (+6.53%)
Oct 7, 2026
20d ago
SC 13G/A
NEUTRAL ★ 3/10
$2.81awaiting T+20—$3.10 (+10.32%)
Oct 1, 2026
25d ago
144
NEUTRAL ★ 2/10
$2.83awaiting T+20—$3.10 (+9.54%)
Sep 21, 2026
5w ago
SC 13G
NEUTRAL ★ 4/10
$3.43 $3.02▼ −11.95%▼ −11.39%$3.10 (−9.62%)
Sep 8, 2026
7w ago
8-K
BULLISH ★ 6/10
$3.51 $2.77▼ −20.97%▼ −22.68%$3.10 (−11.55%)
Aug 13, 2026
10w ago
Insider Cluster
NEUTRAL ★ 2/10
$4.22 $3.62▼ −14.22%▼ −12.23%$3.10 (−26.54%)
Aug 13, 2026
10w ago
144
NEUTRAL ★ 2/10
$4.29 $3.50▼ −18.41%▼ −16.67%$3.10 (−27.74%)
Jun 11, 2026
19w ago
Institutional Cluster
NEUTRAL ★ 2/10
$3.88 $3.96▲ +2.06%▲ +0.17%$3.10 (−20.10%)
Jun 11, 2026
19w ago
Institutional Cluster
NEUTRAL ★ 3/10
$3.88 $3.96▲ +2.06%▲ +0.17%$3.10 (−20.10%)
May 18, 2026
23w ago
EFFECT
NEUTRAL ★ 4/10
$3.68 $4.04▲ +9.78%▲ +8.20%$3.10 (−15.76%)
Showing 10 of 15

US Market Status

Market Open — Closes in 3h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026